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1 INTRODUCTION 
During recent decades, the lungs have been studied as a promising route for the 
administration of drugs for both local treatment and systemic therapy (Clarke et al., 1984, 
Charokopos et al., 2009). The efficiency of treatment is related to the possibility that a 
substantial amount of API (Activa Pharmaceutical Ingredient) reaches the proximal airways, 
where it can exert its therapeutic action. This amount depends on the physiology of breathing 
and mucociliary clearance; the inhaler applied, and the effectiveness of the composition 
characteristics, such as the aerodynamic properties. As the physiological condition of the 
lungs varies individually, scientific studies are required to standardize the delivery systems 
and products (Hinds et al., 1999, Hickey et al., 2006). 
Formulation of the product to be administered by the inhalation route is generally 
complicated, because it involves an active, well-defined product, and a special device. It is 
possible to say that the effectiveness of inhalation therapy, especially for a drug powder 
formulation, is dependent on factors that are related to the patient, the device and the 
characteristics of the formulation (Courrier et al., 2002, Chiara et al., 2008). Among 
pulmonary preparations, dry powder inhalers (DPIs) can ensure stability, a high payload and 
patient convenience (Clarke et al., 1984). The most important parameters of powder for 
inhalation are the particle size, particle size distribution, morphology, crystallinity of the drug 
and dissolution rate (Buckton 1997, Hickey et al., 2006). The DPI quality is assessed by the 
determination of aerodynamic properties (Wong et al., 2010) such as the aerodynamic particle 
size distribution, mass median aerodynamic diameter (MMAD) and fine particle fraction 
(FPF) (Ph. Eur. 7.2. 2012).  
The particle engineering, the type of excipients and the technological processes are 
very important to development of DPI products. Lactose with special habit and its binary 
physical mixtures (API+lactose) are generally used to produce the powder form for 
inhalation. In this relation, novel approach is the use of D-mannitol (M) as a carrier in 
interactive physical mixture (Kaialy et al. 2013). M is a highly water-soluble compound with 
low toxicity, low hygroscopicity, gives an obvious sweet aftertaste.  Another new approach is 
the use of M combination with co-spray-drying technique which results co-spray-dried carrier 
–based microcomposites. 
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2 AIMS 
The primary aim of this study was to establish the literature background of research 
and development work on DPIs. We set out to study the key factors of drugs intended for use 
in powder form for pulmonary delivery. Another objective was to develop a carrier-based, 
crystalline co-spray-dried DPI product containing the low-solubility meloxicam (MX). MX 
can be useful for the mono- and combination treatment of cancer, pulmonary fibrosis, 
inflammation and pain. The pulmonary application of MX is a novelty for local anti-
inflammatory treatment because it does not exhibit aspirin-like hypersensitivity reactivity and 
may therefore be safely applied in therapy. The main steps in our experiments were the 
following: 
i. the identification of important factors in the preformulation for spray-drying, 
preparation and characterization of mannitol (M)-based co-spray-dried samples 
containing MX; 
ii. determination of the cytotoxicity of samples by using Calu-3 cells to screen the safe 
MX concentration for pulmonary delivery, in order to acquire information on the 
availability in pulmonary formulations; 
iii. study of different adjuvants (polymer and amino acid) to optimize the pulmonary 
formulation properties and thereby increase the respirable fraction of co-spray-dried 
samples, investigation of the structure of microcomposites and aerodynamic 
assessment of co-spray-dried powders; 
iv. investigation of the accelerated stability of M-based co-spray-dried products 
containing MX, and the influence of the relative humidity (RH) and temperature on 
the physicochemical properties and aerolization parameters of the microcomposites 
during storage. 
 
A new tendency in the development of DPIs is the design of carrier-based 
microcomposites with a particle size of 3-5 µm as pulmonary drug delivery systems involving 
different carriers and adjuvants. The additives are applied in small amounts in the 
microcomposites in order to promote physicochemical stability, wettability, dispersibility and 
aerodynamic properties. 
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3 MATERIALS AND METHODS 
3.1 Materials 
MX, a DPI-active pharmaceutical ingredient, was obtained from EGIS Ltd. (Hungary), 
β-D-M, a hydrophilic carrier, was obtained from Hungaropharma (Hungary). M is highly 
water-soluble compound with low toxicity, low hygroscopicity and significant stability by the 
DPI formulation. The polymer additives, polyvinylpyrrolidone K-25 (PVP), a stabilizing 
agent, and polyvinyl alcohol 3-88 (PVA), a microfine coating material, were purchased from 
BASF (Germany) and from ISP Customer Service GmBH (Germany), respectively. Tween 80 
(TWEEN), a wetting agent, (BASF, Germany) was of pharmaceutical grade. Amino acids 
such as L-leucine (LEU) (Applichem, Germany) can be co-spray-dried with certain active 
compounds to modify drug aerolization behaviour. 
3.2 Methods 
3.2.1 Formulation of co-spray-dried products containing MX 
The compositions of samples are presented in Table 1. The mass of each sample was 
100 g and Fig. 1. shows the process of formulation of the samples. The preparation 
parameters and the components of the samples were optimized during the process. 
 
Table 1: Compositions of the products. 
Product MX (g) M (g) PVP (g) PVA (g) TWEEN (g) LEU (g) 
MX-M 5 5 - - - - 
MX-M-PVP 5 5 0.025 - - - 
MX-M-PVP-LEU 5 5 0.025 - - 0.2 
MX-M-TWEEN 5 5 - - 0.05 - 
MX-M-TWEEN-LEU 5 5 - - 0.05 0.2 
MX-M-PVA 5 5 - 0.1 - - 
MX-M-PVA-LEU 5 5 - 0.1 - 0.2 
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FIGURE 1: Preparation of co-spray-dried microcomposites. 
 
Each pre-suspension was prepared from MX and M, together with TWEEN, PVP or 
PVA, and with LEU, and made up to 100 g with water, using an Ultraturrax operated at  
24 000 rpm for 10 min. The particle size of the MX in the pre-suspension was decreased by 
cavitation with a high-pressure homogenizator (Avestin Emulsiflex C3, Canada) at 1500 bar 
for 10 cycles. The process resulted in a microsuspension of MX which contained M, PVP or 
PVA and LEU in dissolved form. During the co-spray-drying, the final, solid products were 
obtained, comprising microcomposites containing MX crystals in micronized form. 
On the basis of preformulation studies the composition and the process parameters 
have been modified. The amount of additives was reduced and microfine coating material 
(PVA) and dispersity enhancer (LEU) were applied.  
3.2.2 Cytotoxicity testing 
The Calu-3 cell line was obtained from the American Type Culture Collection (ATCC, 
USA). The MTT method was used to determine the cytotoxicity of the different formulations. 
The absorbance was measured at 570 nm with a FLUOstar OPTIMA microplate reader (BMG 
LABTECH, Offenburg Germany). Absorbance values were corrected for the background 
absorbance, measured at 690 nm. 
3.2.3 Particle size measurement 
The particle size distribution was measured by laser diffraction (Mastersizer S, 
Malvern Instruments Ltd., Worcestershire, UK) with the following parameters: 300RF lens; 
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small volume dispersion unit (1000 rpm); true density of MX = 1.565 g cm
-3
 (AccuPyc 1330, 
Micromeritics, Norcross, USA). The particle size distribution of the microcomposites from 
the dry dispersion unit was also estimated by laser diffraction (Malvern Mastersizer Scirocco 
2000, Malvern Instruments Ltd., Worcestershire, UK. The particle size distribution was 
characterized by the D(0.1), D(0.5) and D(0.9) values and the Span values were calculated. 
3.2.4 Scanning electron microscopy (SEM) 
The morphology of the particles was examined by SEM (Hitachi S4700, Hitachi 
Scientific Ltd., Tokyo, Japan). A sputter coating apparatus (Bio-Rad SC 502, VG Microtech, 
Uckfield, UK) was applied to induce electric conductivity on the surface of the samples. The 
air pressure was 1.3-13.0 mPa. 
3.2.5 Fourier transform infrared spectroscopy (FT-IR) 
FT-IR spectra were recorded with a Bio-Rad Digilab Division FTS- 65A/896 FTIR 
spectrometer (Bio-Rad Digilab Division FTS-65A/869, Philadelphia, USA) between 4000 and 
400 cm
-1
, at an optical resolution of 4 cm
-1
. The sample, with an MX content of 0.5 mg, was 
mixed with 150 mg of dry KBr in an agate mortar, and the mixture was then compressed into 
a disc at 10 tons. Each disc was scanned 64 times at a resolution of 2 cm
-1
 over the 
wavenumber region 4000-400 cm
-1
. 
3.2.6 Contact angle 
The OCA Contact Angle System (Dataphysics OCA 20, Dataphysics Inc., GmbH, 
Germany) was used for studies of the wettability of the carrier systems, and products 
containing MX. 0.15 g of powder was compressed under a pressure of 1 ton by a Specac 
hydraulic press (Specac Inc., USA). 
3.2.7 Water content determination by thermogravimetry (TGA) 
Residual water content was analysed by TG-DTA with a Mettler Toledo TG 821
e
 
thermal analysis system with the STAR
e
 thermal analysis program V9.1 (Mettler Inc., 
Schwerzenbach, Switzerland) under a constant flow of dry nitrogen gas flow of 100 ml min
-1
. 
3.2.8 In vitro release- Modified paddle method 
The paddle method with the USP dissolution apparatus (USP dissolution apparatus, 
type II Pharma Test, Heinburg, Germany) was used to examine MX and the products. The 
medium was 100 ml of phosphate buffer of pH 7.4 ± 0.1 (temperature: 37 ± 1 °C). The basket 
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was rotated at 100 rpm and sampling was performed up to 120 min. The MX contents of the 
samples were determined by spectrophotometry (ATI-UNICAM UV/VIS Spectrophotometer, 
Cambridge, UK) at 362 nm. 
3.2.9 Statistical analysis of MX dissolution profile 
The percentage dissolution efficiency (%DE) for each sample was calculated as the 
percentage ratio of the area under the dissolution curve up to time t to that of the area of the 
rectangle described by 100% dissolution at the same time as follows: 
 (1) 
The mean dissolution time (MDT) was calculated via the following expression: 
 (2) 
where i is the dissolution sample number, n is the number of dissolution times, tmid is the time 
at the midpoint between times ti and ti-1, and ΔM is the amount of MX dissolved (mg) between 
times ti and t i-1. 
3.2.10 In vitro assessment of lung deposition 
The Next Generation Impactor (NGI) was applied in the case of the optimization 
study, and the Andersen Cascade Impactor (ACI) (Copley Scientific Ltd., Nottingham, UK) 
for stability testing. The products were filled into hard gelatine capsules (size 3). The inhaler 
device applied was a plastic RS01 (Plastiape, Italy). Seven stages were coated with a 1% w/v 
Span 85-cyclohexane mixture to control particle rebound. All samples were quantified by 
UV/Vis spectrophotometry at 362 nm. 
3.2.11 Stability testing 
Stability tests were carried out as recommended by the international guidelines 
specified in ICH (International Conference on Harmonization) Q1A (R2) - Stability Testing 
of new Drug Substances and Products. Accelerated testing was performed at 40 ± 2 ºC with 
75 ± 5% RH. Under both conditions, samples were stored in hard gelatine capsules (size 3) 
(Capsugel, Belgium) in open containers; the duration of storage was 6 months. Sampling was 
carried out after 0 and 10 days, and 1, 2, 3 and 6 months. 
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3.2.12 Statistical analysis 
All measurements were carried out in triplicate and values are reported as means ± SD 
unless otherwise noted. Statistical calculations were performed with the software Statistical 
for Windows. To identify statistically significant differences, one-way ANOVA with t-test 
analysis was performed. Probability values of p < 0.05 were considered significant. 
4 Results 
4.1 Preformulation studies of M-based co-spray-dried samples 
The dissolution curves present the dissolution profiles of MX, MX spd and the co-
spray-dried systems (Fig. 2). It was found that the microparticles containing MX showed 
favourable dissolution properties at physiological conditions. The products containing the 
carrier as M and adjuvants (PVP, TWEEN) gave close to 100% release in the first 5 min. The 
dissolution in the first 5 min was ~30 times higher than that for MX. 
 
FIGURE 2: Extent of dissolution of MX from co-spray-died samples in phosphate buffer  
 
Determination of cytotoxicity of spray-dried MX and microcomposites 
Cytotoxicity testing is required for the novel inhalation delivery systems. Ten different 
concentrations of products between 0.01 and 50 mg ml
-1
 were applied, i.e. 0.005-25 mg ml
-1
 
MX content. It was found that, up to a concentration of 0.1 mg ml
-1
 all of the products are 
safely applicable in the lung (Fig. 3). Between 1 and 10 mg ml
-1
, only the MX-M-PVP-
TWEEN products resulted in more than 80% cell viability. 
8 
 
The cytotoxicity tests indicated that, in the case of MX-M-PVP-TWEEN, the dose can 
be increased up to 10 mg ml
-1
, including a maximum of 5 mg ml
-1
 MX, and the applicable 
amount of this drug can therefore be increased 300-fold through use of our formulation. 
 
FIGURE 3: Cytotoxicity of MX spd and products containing MX. 
4.2 Optimization of the specific product parameters and applied additives for the 
aerodynamic assessment of MX 
Size analysis of the co-spray-dried samples revealed that the particle size was typical 
of micronized powders (< 10 µm), which is optimal for pulmonary delivery (Table 2). The 
distribution became homodisperse when LEU was applied. 
 
Table 2: Particle size distributions of dried powders. 
Product  D(0.1) (µm) D(0.5) (µm) D(0.9) µm) 
raw MX 8.56 30.85 63.71 
raw M 5.32 36.37 65.45 
MX-M 1.38 3.09 243.68 
MX-M-PVP 1.65 3.29 6.19 
MX-M-PVP-LEU 1.53 3.05 5.68 
MX-M-TWEEN 2.48 5.09 10.52 
MX-M-TWEEN-LEU 2.08 4.16 8.88 
MX-M-PVA 1.57 3.11 5.81 
 
The crystal morphology is a critical parameter for DPI development, because the 
particle shape affects the aerodynamic behaviour and thus lung deposition. The particles 
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produced with the polymers (PVP and PVA) (C and E) appeared to be spheroidal without 
aggregation, and this could be a beneficial feature in the inhalatory application of these 
powders (Fig. 4). The spherical and regular forms met the requirements for formulation for 
DPIs (MX-M, MX-M-PVA, MX-M-PVP and formulations with LEU). 
 
FIGURE 4: SEM images of MX (A) and M (B) before spray-drying, MX-M-PVP (C), MX-
M-TWEEN (D), MX-M-PVA (E), and a control sample of MX after co-micronization with M 
in a ratio of 1:1 (F). 
 
It was found that the amounts of drug deposited on the throat, on stages 1–7 and on the 
filter, expressed as percentages of the total amount of powder recovered (Fig. 5 and 6) PVP or 
PVA formulated with LEU reduced the impact of MX in the throat (< 20%) and increased its 
deposition in the lowest stages. 
With the exception of the samples containing TWEEN, all of the products exhibited 
favourable aerosolization characteristics, these powder particles impacting on stages 2-5. The 
aerodynamic properties of MX-M-PVP and MX-M-PVA were further improved (p < 0.05) 
when LEU was introduced into the formulation. The FPFs were increased, in both cases to 
more than 53%. The use of LEU as excipient proved effective in reducing the cohesion 
between the particles and improving the powder dispersion delivered from the DPI. 
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FIGURE 5: Drug deposition profiles of co-spray-dried microcomposites in the NGI at 60 l 
min
-1
 via the RS01 (n = 3). 
 
FIGURE 6: Drug deposition profiles of co-spray-dried microcomposites in the NGI at 60 l 
min
-1
 via the RS01 (n = 3). 
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4.3 Physicochemical stability testing and influence of humidity and temperature on 
aerodynamic properties 
Accelerated testing was performed at 40 ± 2 ºC with 75 ± 5% RH. Samples were 
stored in hard gelatine capsules (size 3) (Capsugel, Belgium) in open containers; the duration 
of storage was 6 months. Sampling was carried out after 0 and 10 days, and 1, 2, 3 and 6 
months. 
The spectra revealed no difference in the positions of the absorption bands, especially 
with respect to OH, =O and NH, thereby providing evidence of the absence of H-bonding 
interactions in the solid state between the polymer and MX. In MX-M-PVP-LEU, the 
interactions are reduced during storage, as indicated by the decreases in the associated O-H 
bonds and H-bonding in the interval 3500-3100 cm
-1
 (Fig. 7, 8). The H-bonding did not 
change during storage in the case of MX-M-PVA-LEU. 
 
FIGURE 7: FT-IR analysis of MX-M-PVP-LEU before and after storage. The characteristic 
range is 3500-3100 cm
-1
. 
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FIGURE 8: FT-IR analysis of MX-M-PVA-LEU before and after storage. The characteristic 
range is 3500-3100 cm
-1
. 
 
During stability testing, it can be concluded that PVP or PVA formulated with LEU 
increased the impact of MX in the device and throat and reduced its deposition in the lowest 
stages under both conditions. MX-M-PVA-LEU exhibited favourable aerosolization 
characteristics, these powder particles impacting at a higher rate on stages 2-5, and the 
changes in deposition in the throat and the device after storage were not pronounced. 
 
Table 3: Deposition of co-spray-dried microcomposites in the cascade impactor at 60 l min
-1
 
via RS01 (n = 3). 
Product 
FPD 
(mg) 
FPF 
(%) 
MMAD 
(µm) 
MX-M-PVP-LEU before storage 0.60 ± 0.07 53.05 ± 1.13 3.52 ± 0.13 
MX-M-PVP-LEU after storage 0.24 ± 0.02 41.16 ± 2.81 3.91 ± 0.45 
MX-M-PVA-LEU before storage 0.64 ± 0.05 57.50 ± 1.0 3.04 ± 0.17 
MX-M-PVA-LEU after storage 0.54 ± 0.03 52.5 ± 2.2 3.39 ± 0.11 
 
After storage, the FPFs of the samples were reduced because of the fine particle 
aggregation (Table 3). This is connected with the increased capillary interaction and/or 
moisture adsorption of PVP at higher RH (75%). The FPF of the PVA-containing samples 
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(MX-M-PVA-LEU) was relatively high before storage (57.50 ± 1.0%) and after storage at 
40 ºC and 75% RH was 52.5 ± 2.2%. The MMAD and FPF of the PVA embedded 
formulations did not change significantly during storage. PVP and PVA, as polymer agents, 
exhibited an aggregation-inhibitory effect and ensured the distribution of the individual 
particles. Such particles underwent disaggregation in the air flow of the device and their FPFs 
were improved. 
5 Summary 
The primary aim of this study was to carry out research relating to the development of 
DPI products. We studied the key features of powders for drugs intended for use in 
pulmonary delivery. Another objective was to develop a carrier-based, crystalline co-spray-
dried DPI product containing low-soluble MX. Various approaches to carrier-based 
formulations were investigated in order to enhance the delivery of MX.  
i. The particle size and morphology of the MX and its composites were investigated via 
the additives and the process parameters. Instead of the classical approach based on 
micronization to prepare drug particles followed by blending with a carrier, co-spray-drying 
of the MX/M/additives was performed in an one-step process. Our results point to an 
alternative methodology with which to achieve the rapid release of poorly-soluble drugs.  
ii. Preliminary cell toxicity studies have shown that the use of additives at the given 
concentrations has no effect on the viability of Calu-3 cells over a 24 h period. The minimum 
level of cell viability was higher and non-significantly different from that exhibited with MX 
alone (~ 70%). 
iii. The product parameters were optimized with PVA, PVP, TWEEN and LEU as 
additives in order to improve the drug deposition in the lung. The mean particle size in the M-
based systems was in the required range (3-5 μm). We found that the polymers (PVA and 
PVP) modified the surface of the MX co-sprayed with M and exerted a satisfactory 
aggregation-inhibitory effect, thereby furnishing individual particles. The presence of LEU 
further improved the respirable fraction of MX, and resulted in optimum deposition in the in 
vitro assessment. The FPFs of the microparticles containing the polymers were increased, in 
some cases to more than 53%. Overall, this study has demonstrated that the addition of LEU 
in the MX-M co-spray-dried systems (MX-M-PVA-LEU and MX-M-PVP-LEU) produced 
co-spray-dried inhalation powders containing composite particles applicable for bronchial 
deposition.  
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iv. The accelerated stability testing of M-based co-spray-dried MX-containing DPI 
systems was performed in order to determine the influence of the RH and temperature on the 
physicochemical properties and aerolisation parameters. We found that, MX-M-PVA-LEU 
was stable in the accelerated stability studies; only minor changes were observed in the 
physicochemical properties and aerodynamic performance. 
6 Practical aspects 
This study has demonstrated the ability of micronization of API and spray-drying 
techniques to produce microcomposites containing crystalline MX and with particle 
dimensions suitable for pulmonary administration (< 5 μm). The pulmonary application of 
MX is a novelty for local anti-inflammatory treatment; at present, MX-containing DPI 
products are not marketed for pulmonary therapy. 
 Innovative technology: co-spray-drying of MX from an aqueous microsuspension was 
used to prepare the novelty-type of microcomposites. The final crystalline 
microcomposites is prepared in an one-step process, which additionally ensures the 
respirable particle size range (3-5 µm), the spherical form and crystallinity property of 
the product. 
 Innovative product: The formulated microcomposite is new tendency in pulmonary 
drug delivery. The hydrophilic carrier (M) and additives (PVP, PVA, LEU) are located 
on the surface of the API with a hydrophobic character therefore the microcomposites 
result in the rapid drug release. M was primarily chosen as a carrier in this study 
because its particle size can be readily controlled by spray-drying and the spray-dried 
powder is crystalline and physically stable. The sample containing PVA proved to be 
stable in accelerated stability studies, and is an innovative product which may be 
considered suitable for scaled-up processes and pulmonary application. 
 
The innovative technology and product appear to be of great potential in 
pulmonary drug delivery systems. 
 
  
 
PUBLICATIONS RELATED TO THE SUBJECT OF THE THESIS 
 
1. Pomázi A., Ambrus R., Sipos P., Kása P., Szabó-Révész P. 
Formulation of Meloxicam microparticles for dry powder inhalation 
Pharmaceutical Journal of Slovenia 59 (2008) 119-121. 
IF:- 
 
2. Pomázi Anita, Szabóné Révész Piroska, Ambrus Rita 
Pulmonális gyógyszerbevitel, DPI készítmények formulálásának szempontjai 
Gyógyszerészet 53 (2009) 397-404. 
IF.: -  
 
3. Ambrus R., Pomázi A., Réti-Nagy K., Fenyvesi F., Vecsernyés M., Szabó-Révész P. 
Cytotoxicity testing of carrier-based microcomposites for DPI application 
Pharmazie 66 (2011) 549-550. 
IF.: 0.869 
 
4. Pomázi A., Ambrus R., Sipos P., Szabó-Révész P. 
Analysis of co-spray-dried meloxicam-mannitol systems containing crystalline 
microcomposites 
Journal of Pharmaceutical Biomedical Analysis 56 (2011) 183-190. 
IF.: 2.733 
 
5. Pomázi A., Buttini F, Ambrus R., Colombo P., Révész P. 
Effect of polymers for aerolisation properties of mannitol-based microcomposites 
containing meloxicam 
European Polymer Journal 49 (2013) 2518-2527. 
IF: 2.739 
 
6. Pomázi A, Ambrus R., Szabó-Révész P. 
Physicochemical stability and aerolization performance of mannitol-based 
microcomposites 
Journal of Drug Delivery Science and Technology 
accepted for publication (2014) 
IF: 1,088 
 
OTHER PUBLICATIONS 
 
1. Ambrus R., Pomázi A., Aigner Z., Kocbek P., Kristl J. Szabóné Révész P. 
Nanotechnológia, nanokristályok a gyógyszerformulálásban 
Gyógyszerészet 52 (2008) 259-264 
IF.:-  
 
2. Pomázi A., Ambrus R., Sipos P., Otomo N., Szabó-Révész P. 
Effect of a sucrose ester on co-micronized mannitol-based drug formulation 
European Journal of Pharmaceutical Sciences 38 (1) (2009) Suppl. 73-74 
IF.: -  
 
  
 
3. Ambrus R., Pomázi A., Szabóné-Révész P. 
A nanotechnológia mint új irányvonal a hatóanyagkristályok formulálásában 
Magyar Kémiai Folyóirat 3 (2010) 96-100 
IF.: - 
 
4. Ambrus R., Pomázi A., Kristl J., Kocbeck P., Szabó-Révész P. 
Effect of high-pressure homogenization on the formulation of micro- and nanocrystals 
containing poorly watersoluble meloxicam 
Scientia Pharmaceutica 2010. 78: 571 doi:10.3797/scipharm.cespt.8.LNM03 
IF.: - 
 
PRESENTATIONS RELATED TO THE SUBJECT OF THE THESIS 
 
Oral presentations 
Pomázi Anita 
Mikrorészecskék előállítása és vizsgálata porinhalációs készítmények formulálása céljából I. 
Szent-Györgyi Albert Szakkollégium Konferencia 
Budapest, 2008. március. 
 
Pomázi Anita 
Lokális hatású porinhalációs rendszerek fejlesztése és gyógyszerforma vizsgálata 
X. Clauder Ottó emlékverseny 
Budapest, 2011. október. 
 
Pomázi A., Ambrus R., Révész P. 
Meloxicam tartalmú porinhalációs rendszerek fejlesztése és stabilitásának vizsgálata 
Gyógyszerkémiai és Gyógyszertechnológiai Szimpózium '12 
Debrecen, 2012. szeptember 13-14. 
 
Pomázi A., Ambrus R., Révész P. 
Meloxicam-tartalmú porinhalációs készítmény stabilitásának vizsgálata 
XVII. Gyógyszertechnológiai és IX. Gyógyszer az ezredfordulón konferencia 
Siófok, 2012. szeptember 27-29. 
 
Poster presentations 
A. Pomázi, R. Ambrus, P. Sipos, P. Kása, P. Szabó-Révész 
Formulation of Meloxicam microparticles for dry powder inhalation 
7th Central European Symposium on Pharmaceutical Technology & Biodelivery Systems 
Ljubljana, Slovenia, September 2008. 
 
A. Pomázi., F. Buttini., R. Ambrus., P. Colombo., P. Szabó-Révész 
Development of dry powder formulations of meloxicam for pulmonary therapy 
8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology 
Istanbul, 2012. March 19-22. 
  
 
A. Pomázi., F. Buttini., R. Ambrus., P. Colombo., P. Szabó-Révész 
Effect of polymers for aerolisation properties of mannitol-based microcomposites containing 
meloxicam 
Advanced Macromolecular Systems Across the Length Scales Symposium 
Siófok, 2012. június 3-6. 
  
 
Financial support 
 
This research was supported by the European Union and the State of Hungary, co-
financed by the European Social Fund in the framework of TÁMOP 4.2.4. A/2-11-
1-2012-0001 ‘National Excellence Program’. 
 
